Abstract
The development of small-molecule tyrosine kinase inhibitors remains a high-priority strategy in modern oncology, particularly those targeting the Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) to disrupt pathological angiogenesis. This study utilized a dual-methodology approach to evaluate a novel series of five coumarin nucleoside conjugates (5a-5e) as potential anti-cancer agents. Initially, the compounds' drug-likeness was confirmed via ADMET prediction, which established favorable pharmacokinetic profiles. This was followed by an integrated MTT cytotoxicity screening against Oct1 (head and neck) and C33a (cervical) cancer cell lines, which identified compound 5d as the most potent cellular agent. The core of the investigation involved a comprehensive in silico analysis targeting the VEGFR-2 tyrosine kinase domain (TKD). Molecular docking revealed that all five compounds possess significantly superior predicted binding affinities compared to the native ligand, ATP (- 25.44 kJ/mol). Critically, the primary cellular lead 5d (- 29.46 kJ/mol) and the strongest binder 5e (- 31.30 kJ/mol) both surpassed the affinity of the clinical benchmark, Sorafenib (- 28.80 kJ/mol), confirming their high potential as competitive inhibitors. Further validation using Molecular Dynamics (MD) simulation and MMPBSA analysis demonstrated exceptional dynamic stability and thermodynamic preference for the TKD-ligand complexes, firmly supporting the predicted binding hypothesis. In conclusion, compounds 5d and 5e are validated lead candidates possessing favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, direct cellular cytotoxicity, and a robust computationally modeled dual-action profile. Future research is urgently mandated to perform VEGFR-2-specific functional assays to definitively validate the predicted anti-angiogenic mechanism and conduct in-vivo studies to assess therapeutic efficacy.